Natera has introduced new features to its Prospera Heart test, aimed at improving the detection of rejection in heart transplant patients. The newest features of the test leverages the novel Donor Quantity Score (DQS) technique. DQS is a new metric that normalizes for the background total cfDNA, enhancing donor-derived cell-free DNA (dd-cfDNA) tests for more accurate risk assessment in transplant rejection cases.
DQS is combined with the traditional donor fraction in a two-threshold algorithm, providing a single risk analysis result for antibody-mediated rejection (AMR) and acute cellular rejection (ACR). The company claims this feature will help avoid unnecessary biopsies and follow-up procedures.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.